We used this hypothesis validation workflow to filter the list of 29 candidate targets to five top-tier targets that both impact relevant phenotypes and induce proteomic changes that reverse AD-associated signatures: AP2A2, PDHB, PDHA1, DLAT, and PSMC3. This evidence concerns the gene PDHB and Alzheimer disease.